Ahammune Biosciences raises Pre-Series A funding from Ideaspring Capital, Indian Angel Network
April 26, 2021
, March 26
Pune-based biotech start-up company Ahammune Biosciences has raised an undisclosed amount in a Pre-Series A round led by Ideaspring Capital and Indian Angel Network.
Kotak Private Equity, Legacy Assets LLP (Baldota family fund) and Ajith Kamath (ex-Pfizer) have also participated in the round along with existing investors, including Anand Deshpande and Suman Kant Munjal. The Company also has Ganesh Natarajan as an existing investor and has been in receipt of funding grant from Government of India’s body, BIRAC.
The freshly-infused capital will be used for “first-in-human” studies with Ahammune’s new drug candidate AB1001 for vitiligo. The study will comprise Phase-I safety studies in healthy human volunteers and Phase-II efficacy studies in vitiligo patients. The company will also deploy the funds in building the patent portfolio to further the resear